All In MedTech

Device Trial Radar · NCT05302050

A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Oct 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

500

Actual

Start

Mar 7, 2022

Primary completion

Dec 1, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Better TherapeuticsNot on our public-company list
Sponsor type
Industry
Collaborators
Massachusetts General Hospital
First posted
Mar 31, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized, controlled, pragmatic trial with open-label extension evaluating BT-001, an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control.

Conditions

  • Diabetes Type 2

Interventions

  • BT-001Device

    BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone. The behavioral intervention process involves: Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs. Each week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily.

  • Control Mobile ApplicationDevice

    The app asks patients brief questions about their health but does not include any behavioral therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: Baseline and Day 180

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mass General Brigham Hospital and Clinics

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.